{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:34:22Z","timestamp":1790739262071,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Seena Magowitz Foundation"},{"name":"Translational Genomics Research Institute National Advisory Council, Michael and Mary Ellen Francis"},{"name":"HonorHealth Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For patients with untreated pancreatic ductal adenocarcinoma (PDAC), chemotherapy before surgery (\u201cneoadjuvant therapy\u201d) has shown benefit in reducing recurrence and prolonging survival. Targeting the vitamin D receptor (VDR) with analogs such as paricalcitol may improve chemotherapy effectiveness. This study evaluated the efficacy and safety of neoadjuvant albumin-bound paclitaxel (nab-paclitaxel) plus cisplatin plus gemcitabine (NABPLAGEM) plus paricalcitol (NCT03138720).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants were \u226518\u2009years, had stage I-III PDAC without prior chemotherapy or radiation, Karnofsky Performance Status \u226570, and elevated CA 19-9. Study treatment included nab-paclitaxel (125\u2009mg\/m2), cisplatin (25\u2009mg\/m2), gemcitabine (1000\u2009mg\/m2), and paricalcitol (25\u2009mcg) on days 1 and 8 of a 21-day cycle for up to 6 months. The primary outcome was CA 19-9 normalization. Secondary outcomes included margin-negative resection (R0), pathologic complete response (pCR), radiologic response, safety, and survival. Microbiome was analyzed as an exploratory outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-two participants were enrolled with median age 69.4\u2009years, 56.2% male, and 93.8% white. Patients had resectable (cohort A, n\u2009=\u200910) and borderline resectable\/locally advanced (cohort B, n\u2009=\u200922) tumors. CA 19-9 normalization occurred in 14 patients (43.8%). Two patients (6.2%) achieved pCR, and 19 (59.4%) achieved R0. Complete or partial radiologic response occurred in 39.3% of patients. Adverse events included grade 3-4 anemia (43.8%) and thrombocytopenia (59.4%). Median (95% CI) overall survival was 43.2 (7.5\u2013upper bound not achieved) and 18.4 (10.9-41.2) months for cohorts A and B, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Neoadjuvant NABPLAGEM plus paricalcitol demonstrated a high CA 19-9 normalization rate and was fairly well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag232","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:50:04Z","timestamp":1781092204000},"source":"Crossref","is-referenced-by-count":2,"title":["A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8990-4684","authenticated-orcid":false,"given":"Alexa F","family":"Viniotis","sequence":"first","affiliation":[{"name":"HonorHealth Research Institute - Oncology Department , Scottsdale, AZ 85258,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0987-5965","authenticated-orcid":false,"given":"Gayle S","family":"Jameson","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute - Oncology Department , Scottsdale, AZ 85258,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2470-3440","authenticated-orcid":false,"given":"Betsy C","family":"Wertheim","sequence":"additional","affiliation":[{"name":"University of Arizona Cancer Center - Biostatistics Department , Tucson, AZ 85704,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6989-6579","authenticated-orcid":false,"given":"Denise J","family":"Roe","sequence":"additional","affiliation":[{"name":"University of Arizona Cancer Center - Biostatistics Department , Tucson, AZ 85704,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1751-3043","authenticated-orcid":false,"given":"Keehoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Translational Genomics Research Institute North - Immunology and Microbiome Division , Flagstaff, AZ 86005,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5233-2466","authenticated-orcid":false,"given":"Frank Y","family":"Tsai","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute - Oncology Department , Scottsdale, AZ 85258,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7679-9504","authenticated-orcid":false,"given":"Michael S","family":"Gordon","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute - Oncology Department , Scottsdale, AZ 85258,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1308-5985","authenticated-orcid":false,"given":"Sunil","family":"Sharma","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute - Oncology Department , Scottsdale, AZ 85258,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol M","family":"Guarnieri","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute - Oncology Department , Scottsdale, AZ 85258,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney E","family":"Snyder","sequence":"additional","affiliation":[{"name":"Snyder Patient Advocacy and Navigation , Cave Creek, AZ 85331,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar J","family":"Thosani","sequence":"additional","affiliation":[{"name":"HonorHealth Scottsdale Shea Medical Center - Interventional Gastroenterology , Scottsdale, AZ 85258,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Amini","sequence":"additional","affiliation":[{"name":"Arizona Premier Surgery - General Surgery , Scottsdale, AZ 85258,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E","family":"Sckolnik","sequence":"additional","affiliation":[{"name":"Arizona Center for Cancer Care - Radiation Oncology , Scottsdale, AZ 85258,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6386-7889","authenticated-orcid":false,"given":"Jacqueline M","family":"Garrick","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute - Oncology Department , Scottsdale, AZ 85258,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L","family":"Korn","sequence":"additional","affiliation":[{"name":"Imaging Endpoints - Radiology , Scottsdale, AZ 85251,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2507-8755","authenticated-orcid":false,"given":"Syed","family":"Rahmanuddin","sequence":"additional","affiliation":[{"name":"National Medical Center & Beckman Research Institute, City of Hope Comprehensive Cancer Center - Department of Diagnostic Radiology , Duarte, CA 91010,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9986-5965","authenticated-orcid":false,"given":"Ronald M","family":"Evans","sequence":"additional","affiliation":[{"name":"The Salk Institute - Gene Expression Laboratory , La Jolla, CA 92037,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6351-9585","authenticated-orcid":false,"given":"Michael","family":"Downes","sequence":"additional","affiliation":[{"name":"The Salk Institute - Gene Expression Laboratory , La Jolla, CA 92037,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Truitt","sequence":"additional","affiliation":[{"name":"The Salk Institute - Gene Expression Laboratory , La Jolla, CA 92037,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4723-7681","authenticated-orcid":false,"given":"Daniel D","family":"Von Hoff","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute - Oncology Department , Scottsdale, AZ 85258,","place":["United States"]},{"name":"Translational Genomics Research Institute - Clinical Genomics and Therapeutics Division , Phoenix, AZ 85004,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-5462","authenticated-orcid":false,"given":"Erkut H","family":"Borazanci","sequence":"additional","affiliation":[{"name":"HonorHealth Research Institute - Oncology Department , Scottsdale, AZ 85258,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2026072113063780400_oyag232-B1","year":"2009"},{"key":"2026072113063780400_oyag232-B2","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N Engl J Med."},{"key":"2026072113063780400_oyag232-B3","doi-asserted-by":"publisher","first-page":"e70043","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin."},{"key":"2026072113063780400_oyag232-B4","author":"Cancer of the Pancreas\u2014Cancer Stat Facts"},{"key":"2026072113063780400_oyag232-B5","year":"2026"},{"key":"2026072113063780400_oyag232-B6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13304-021-01186-1","article-title":"Neoadjuvant therapy for pancreatic cancer","volume":"74","author":"Gugenheim","year":"2022","journal-title":"Updates Surg."},{"key":"2026072113063780400_oyag232-B7","doi-asserted-by":"publisher","first-page":"100804","DOI":"10.1016\/j.ctarc.2024.100804","article-title":"Neoadjuvant treatment for pancreatic cancer: controversies and advances","volume":"39","author":"Dias e Silva","year":"2024","journal-title":"Cancer Treat Res Commun."},{"key":"2026072113063780400_oyag232-B8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1001\/jamaoncol.2019.3394","article-title":"Response rate following albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: a phase 1b\/2 pilot clinical trial","volume":"6","author":"Jameson","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026072113063780400_oyag232-B9","year":"2019"},{"key":"2026072113063780400_oyag232-B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cam4.7412","article-title":"Phase II clinical trial of nab-paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer","volume":"13","author":"Jameson","year":"2024","journal-title":"Cancer Med."},{"key":"2026072113063780400_oyag232-B11","year":"2023"},{"key":"2026072113063780400_oyag232-B12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","article-title":"Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy","volume":"159","author":"Sherman","year":"2014","journal-title":"Cell."},{"key":"2026072113063780400_oyag232-B13","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4161\/cbt.7.3.5418","article-title":"19-nor-1\u03b1,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo","volume":"7","author":"Schwartz","year":"2008","journal-title":"Cancer Biol Ther."},{"key":"2026072113063780400_oyag232-B14","doi-asserted-by":"publisher","first-page":"101881","DOI":"10.1016\/j.xcrm.2024.101881","article-title":"Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine","volume":"6","author":"Nagaraju","year":"2025","journal-title":"Cell Rep Med."},{"key":"2026072113063780400_oyag232-B15","year":"2025"},{"key":"2026072113063780400_oyag232-B16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/SLA.0000000000004155","article-title":"Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine\/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma","volume":"272","author":"Ahmad","year":"2020","journal-title":"Ann Surg."},{"key":"2026072113063780400_oyag232-B17","year":"2022"},{"key":"2026072113063780400_oyag232-B18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/SLA.0000000000005184","article-title":"Prognosis associated with CA19-9 response dynamics and normalization during neoadjuvant therapy in resected pancreatic adenocarcinoma","volume":"277","author":"Newhook","year":"2023","journal-title":"Ann Surg."},{"key":"2026072113063780400_oyag232-B19","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1001\/jamasurg.2020.2286","article-title":"Response and survival associated with first-line FOLFIRINOX vs gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma","volume":"155","author":"Perri","year":"2020","journal-title":"JAMA Surg."},{"key":"2026072113063780400_oyag232-B20","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/SLA.0000000000003049","article-title":"Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer","volume":"271","author":"Tsai","year":"2020","journal-title":"Ann Surg."},{"key":"2026072113063780400_oyag232-B21","doi-asserted-by":"publisher","first-page":"100552","DOI":"10.1016\/j.esmoop.2022.100552","article-title":"Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)","volume":"7","author":"Hartlapp","year":"2022","journal-title":"ESMO Open."},{"key":"2026072113063780400_oyag232-B22","year":"2021"},{"key":"2026072113063780400_oyag232-B23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer (1965)"},{"key":"2026072113063780400_oyag232-B24","year":"2026"},{"key":"2026072113063780400_oyag232-B25","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41587-019-0209-9","article-title":"Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2","volume":"37","author":"Bolyen","year":"2019","journal-title":"Nat Biotechnol."},{"key":"2026072113063780400_oyag232-B26","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1038\/s41467-020-17041-7","article-title":"Analysis of compositions of microbiomes with bias correction","volume":"11","author":"Lin","year":"2020","journal-title":"Nat Commun."},{"key":"2026072113063780400_oyag232-B27","doi-asserted-by":"publisher","first-page":"678617","DOI":"10.3389\/fonc.2021.678617","article-title":"Role of 3D volumetric and perfusion imaging for detecting early changes in pancreatic adenocarcinoma","volume":"11","author":"Rahmanuddin","year":"2021","journal-title":"Front Oncol"},{"key":"2026072113063780400_oyag232-B28","doi-asserted-by":"publisher","author":"Wolpin","DOI":"10.1158\/1538-7445.AM2026-LB407"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag232\/68504803\/oyag232.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag232\/68504803\/oyag232.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag232\/68504803\/oyag232.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T17:06:44Z","timestamp":1784653604000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag232\/8705149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag232","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,6]]},"article-number":"oyag232"}}